Dr Rani Pallavi
Designation: Research Scientist, DBT Ramalingaswami Fellow, Ocular Oncology Specialisation:Cancer biology, drug discovery,
and in vivo preclinical models Email: rani.pallavi@lvpei.org Location: Kallam Anji Reddy Campus, Hyderabad
Dr Rani Pallavi obtained her PhD in biochemistry from the esteemed Indian Institute of Science. After receiving a SIPOD-Marie Curie Incoming Fellowship for foreigners from SEMM, she joined the Department of Experimental Oncology in Milan, Italy, as a Postdoctoral fellow. Later, she obtained an AIRC-Marie Curie fellowship to develop her research project focusing on the effect of caloric restriction on tumour initiation and progression.
During her postdoctoral tenure, she delved into innovative therapeutic strategies for cancer. During this period, she gained extensive training as a cancer biologist and accumulated over a decade of experience in preclinical and translational research. Demonstrating her capability, she led preclinical studies focusing on mechanistic investigations into dietary interventions, drug discovery, and biomarker identification. Dr Rani Pallavi has comprehensive expertise and proficiency in cutting-edge omic technologies, such as genomics, transcriptomics, and single-cell technologies.
Dr Rani Pallavi has been honoured with numerous fellowship awards, both nationally and internationally. Additionally, she received the Young Investigator award from the Ministry of Health in Italy. She was recently granted the Ramalingaswami Re-entry Fellowship by the Department of Biotechnology, Government of India, for the year 2022-2023. Her research accomplishments have been recognized with patents and publications in esteemed journals, including Nature Communications. Driven by a profound dedication, she is deeply committed to leveraging her research endeavours for the betterment of patients' lives.
Dr Rani Pallavi's research is not just about understanding the complexities of retinoblastoma chemotherapy resistance and metastasis. It's about pushing the boundaries of knowledge and innovation. She views tumour heterogeneity as a crucial determinant of drug response and plans to tackle this challenge with an ambitious approach. Her strategy involves integrating multi-level analyses of primary human tumours, encompassing cell lines, organoids, and patient-derived xenografts alongside zebrafish xenograft models. This comprehensive strategy aims to unravel and harness tumour susceptibility factors. Furthermore, her research also focuses on identifying biomarkers to enhance diagnosis and guide treatment decisions.